With lives at stake, there’s no time to waste. The Alastair Lucas Prize for Medical Research allows the highest calibre researchers to immediately start life-saving work.
Funded by the National Institute of Health (NIH), Baltimore (USA), Burnet Institute and the Kirby Institute (Sydney) Baltimore (USA) undertook a study of the treatment of acute hepatitis C (HCV) with a 24-week course of pegylated interferon (modified interferon molecule administered weekly by subcutaneous injection) with or without Ribavirin.
ATAHC II involved following a longitudinal, non-randomised cohort with a treatment and non-treatment arm. Injecting drug users were not excluded from this study.
The study was approved by Alfred Health Human Ethics and recruitment.
The Kirby Institute, Sydney, Australia
National Institutes of Health, Baltimore, USA